Business Continuity Risk from the Spread of Infectious Diseases
First written in FY2021. 3 of 5 entries say "Restated". Latest entry: FY2023-Q3.
The whole theme swung hardest in 2025: 2 of 12 companies on the "Worse" side.
18 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no material changes or newly arising risks from those described in the annual securities report for the previous fiscal year regarding business and other risks that could materially affect investors' decisions.」
The disclosure reconfirms that there have been no significant changes or new risks from the prior year's disclosure concerning business continuity risk from the spread of infectious diseases. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes or newly arising risks from those described in the annual securities report for the previous fiscal year regarding business and other risks that could materially affect investors' decisions.」
The disclosure reconfirms that there have been no significant changes or new risks from the prior year's disclosure concerning business continuity risk from the spread of infectious diseases. - FY2022MitigatedAnnual report
「To prevent infections among officers and employees, we conducted workplace vaccinations against COVID-19 for officers, employees and their family members.」
In addition to existing measures such as working from home and dispersing operations across locations, we conducted workplace vaccinations for officers, employees and their family members. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes or newly arising risks from those described in the annual securities report for the previous fiscal year regarding business and other risks that could materially affect investors' decisions.」
The disclosure states that there have been no significant changes or new risks from the prior year's disclosure concerning business continuity risk from the spread of infectious diseases. - FY2021First statedAnnual report
「If an infectious disease such as COVID-19 becomes widespread globally and a large number of our group's officers and employees become infected, it could become difficult to continue all or part of our operations and affect the business performance and financial condition of our group.」
The disclosure identified employee infections and difficulty continuing operations due to infectious diseases as a separate risk, citing partitions, masks, staggered shifts, dispersed locations and working from home as countermeasures.